[Pyoderma gangrenosum: successful topical therapy with tacrolimus (FK506)].
Pyoderma gangrenosum is a distinct clinical entity characterized by chronic, recurring, destructive ulcerations. Although the pathogenesis of pyoderma gangrenosum is unknown, immunologic aberrations of neutrophil granulocytes seem to be important. Systemic steroids and macrolide lactones such as cyclosporin A and tacrolimus have been reported to be useful in the clinical management of disease. Pyoderma gangrenosum has been found to be associated with several systemic diseases. The association with chronic ulcerative colitis is well known, but the diagnosis may be complicated by early administration of systemic steroids. Therefore, local immunosuppression with topically applied agents could be an efficient therapeutic alternative especially for mild or early cutaneous lesions.We describe the successful topical treatment of a patient with multiple lesions of pyoderma gangrenosum with 0,1% tacrolimus (FK506) ointment which is known to have better dermal penetration and higher immunosuppressive potency than topical cyclosporin A. In addition, other indications for topical tacrolimus are discussed.
Petering
H
H
Dermatologische Klinik und Poliklinik, Medizinische Hochschule Hannover. h_petering@csi.com
Kiehl
P
P
Breuer
C
C
Kapp
A
A
Werfel
T
T
D000005:Abdomen / Q000000981:diagnostic imaging; D000328:Adult; D003093:Colitis, Ulcerative / Q000150:complications / Q000175:diagnosis; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D009824:Ointments; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016559:Tacrolimus / Q000008:administration & dosage*; D013997:Time Factors; D014463:Ultrasonography
D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus
Pyoderma gangraenosum: erfolgreiche topische Therapie mit Tacrolimus (FK506).